• Helyx Industries secured European Patent Office approval for a patent covering its proprietary deep multiplexing technology.
• The European approval follows a US patent grant announced in May, extending protection across the two largest molecular diagnostics markets.
• The patent covers human papillomavirus genotyping methods and diagnostic kits through 20 claims.
• The technology supports the Vytro division's multiplex molecular diagnostics offering, identifying multiple DNA targets in a single PCR reaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Helyx Industries S.p.A. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.